IL6 and macrophage activation syndrome: The inhibition of IL-1 (with the use of anakinra and canakinumab) and IL-6 (mainly with tocilizumab) showed a strong efficacy compared with placebo in several cohorts and randomized controlled trials in MAS-HLH and AOSD.